Business
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT\nMarlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.\nMr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Wednesday, October 23, 2024, at 12 PM EDT. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.\nPhio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.\nREGISTER HERE:\nhttps://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-phio-mt_JoV6sap\nTo ensure smooth connectivity, please access the link above using the latest version of Google Chrome.\nAbout Phio Pharmaceuticals Corp.\nPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. In non-systemic applications, INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.\nFor additional information, visit the Company's website, www.phiopharma.com.\nForward Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as \"intends,\" \"believes,\" \"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\" \"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\" \"forecast,\" \"target,\" \"predict,\" \"could\" and similar references, although not all forward-looking statements co...